@article{a98057561c8d454da19823515609dbcb,
title = "Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma",
keywords = "Metastatic renal cell carcinomas, Immunotherapy, Nivolumab, Ipilimumab, Second-line tyrosine kinase inhibitors, Outcomes, DOSE RECOMBINANT INTERLEUKIN-2, CLINICAL-PRACTICE GUIDELINES, INTERFERON-ALPHA, SUNITINIB, CANCER, SURVIVAL, BLOCKADE, 3122 Cancers",
author = "Marie Auvray and Edouard Auclin and Philippe Barthelemy and Petri Bono and Pirkko Kellokumpu-Lehtinen and Marine Gross-Goupil and {De Velasco}, Guillettno and Thomas Powles and Guillaume Mouillet and Yann-Alexandre Vano and Gwenaelle Gravis and Loic Mourey and Franck Priou and Frederic Rolland and Bernard Escudier and Laurence Albiges",
note = "Correction: Volume: 119 Pages: 200-201 DOI: 10.1016/j.ejca.2019.04.012 Published: SEP 2019",
year = "2019",
month = feb,
doi = "10.1016/j.ejca.2018.11.031",
language = "English",
volume = "108",
pages = "33--40",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER SCI IRELAND LTD",
}